Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer

Journal of Immunology

Volumn 173, Issue 3, 2004, Pages 2143-2150

  Kershaw, Michael H ^a   Jackson, Jacob T ^a   Haynes, Nicole M ^a   Teng, Michele W L ^a   Moeller, Maria ^a   Hayakawa, Yoshihiro ^a   Street, Shayna E ^a   Cameron, Rachel ^a   Tanner, Jane E ^a   Trapani, Joseph A ^a   Smyth, Mark J ^a   Darcy, Philip K ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CHIMERIC RECEPTOR; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GAMMA INTERFERON; RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CELL SPECIFICITY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RELEASE; DNA MODIFICATION; GENETIC ENGINEERING; IN VITRO STUDY; LIVER METASTASIS; LUNG METASTASIS; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; T LYMPHOCYTE; TUMOR CELL DESTRUCTION;

EID: 3242765879     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.3.2143     Document Type: Article

References (41)

1. Fossati, R., C. Confalonieri, V. Torri, E. Ghislandi, A. Penna, V. Pistotti, A. Tinazzi, and A. Liberati. 1998. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J. Clin. Oncol. 16:3439.
2. Bergh, J., P. E. Jonsson, B. Glimelius, and P. Nygren. 2001. A systematic overview of chemotherapy effects in breast cancer. Acta Oncol. 40:253.
3. Henderson, R. A., and O. J. Finn. 1996. Human tumor antigens are ready to fly. Adv. Imunol. 62:217.
4. Press, M. F., C. Cordon-Cardo, and D. J. Slamon. 1990. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5:953.
5. Disis, M. L., and M. A. Cheever. 1997. HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv. Cancer Res. 71:343.
6. Keefe, D. L. 2002. Trastuzumab-associated cardiotoxicity. Cancer 95:1592.
7. Cobleigh, M. A., C. L. Vogel, D. Tripathy, N. J. Robert, S. Scholl, L. Fehrenbacher, J. M. Wolter, V. Paton, S. Shak, G. Lieberman, and D. J. Slamon. 1999. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17:2639.
8. Vogel, C. L., M. A. Cobleigh, D. Tripathy, J. C. Gutheil, L. N. Harris, L. Fehrenbacher, D. J. Slamon, M. Murphy, W. F. Novotny, M. Burchmore, et al. 2002. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20:719.
9. Eshhar, Z., T. Waks, G. Gross, and D. G. Schindler. 1993. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA 90:720.
10. Hwu, P., G. E. Shafer, J. Treisman, D. G. Schindler, G. Gross, R. Cowherd, S. A. Rosenberg, and Z. Eshhar. 1993. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor γ chain. J. Exp. Med. 178:361.
11. Haynes, N. M., J. A. Trapani, M. W. Teng, J. T. Jackson, L. Cerruti, S. M. Jane, M. H. Kershaw, M. J. Smyth, and P. K. Darcy. 2002. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 100:3155.
12. Lamers, C. H., R. A. Willemsen, B. A. Luider, R. Debets, and R. L. Bolhuis. 2002. Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer. Cancer Gene Ther. 9:613.
13. Brentjens, R. J., J. B. Latouche, E. Santos, F. Marti, M. C. Gong, C. Lyddane, P. D. King, S. Larson, M. Weiss, I. Riviere, and M. Sadelain. 2003. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 9:279.
14. Patel, S. D., Y. Ge, M. Moskalenko, and J. G. McArthur. 2000. Anti-tumor CC49-ζ CD4 T cells possess both cytolytic and helper functions. J. Immunother. 23:661.
15. Gilham, D. E., A. O'Neil, C. Hughes, R. D. Guest, N. Kirillova, M. Lehane, and R. E. Hawkins. 2002. Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3ζ-based chimeric immune receptors. J. Immunother. 25:139.
16. Rossig, C., C. M. Bollard, J. G. Nuchtern, C. M. Rooney, and M. K. Brenner. 2002. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood 99:2009.
17. Stancovski, I., D. G. Schindler, T. Waks, Y. Yarden, M. Sela, and Z. Eshhar. 1993. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J. Immunol. 151:6577.
18. Moritz, D., W. Wels, J. Mattern, and B. Groner. 1994. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc. Natl. Acad. Sci. USA 91:4318.
19. Altenschmidt, U., R. Kahl, D. Moritz, B. S. Schnierle, B. Gerstmayer, W. Wels, and B. Groner. 1996. Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes. Clin. Cancer Res. 2:1001.
20. Haynes, N. M., M. J. Smyth, M. H. Kershaw, J. A. Trapani, and P. K. Darcy. 1999. Fas-ligand-mediated lysis of erbB-2-expressing tumor cells by redirected cytotoxic T lymphocytes. Cancer Immunol. Immunother. 47:278.
21. Altenschmidt, U., E. Klundt, and B. Groner. 1997. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression. J. Immunol. 159:5509.
22. Eshhar, Z., T. Waks, A. Bendavid, and D. G. Schindler. 2001. Functional expression of chimeric receptor genes in human T cells. J. Immunol. Methods 248:67.
23. Finney, H. M., A. D. Lawson, C. R. Bebbington, and A. N. Weir. 1998. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J. Immunol. 161:2791.
24. Haynes, N. M., J. A. Trapani, M. W. Teng, J. T. Jackson, L. Cerruti, S. M. Jane, M. H. Kershaw, M. J. Smyth, and P. K. Darcy. 2002. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J. Immunol. 169:5780.
25. Maher, J., R. J. Brentjens, G. Gunset, I. Riviere, and M. Sadelain. 2002. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nat. Biotechnol. 20:70.
26. Aslakson, C. J., and F. R. Miller. 1992. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52:1399.
27. Pulaski, B. A., and S. Ostrand-Rosenberg. 1998. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 58:1486.
28. Lelekakis, M., J. M. Moseley, T. J. Martin, D. Hards, E. Williams, P. Ho, D. Lowen, J. Javni, F. R. Miller, J. Slavin, and R. L. Anderson. 1999. A novel orthotopic model of breast cancer metastasis to bone. Clin. Exp. Metastasis 17:163.
29. Wels, W., I. M. Harwerth, M. Mueller, B. Groner, and N. E. Hynes. 1992. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res. 52:6310.
30. Rosenberg, S. A. 2000. Principles and Practice of the Biologic Therapy of Cancer, 3rd Ed. Lippincott, Williams and Wilkins, Baltimore.
31. Izumi, Y., L. Xu, E. di Tomaso, D. Fukumura, and R. K. Jain. 2002. Tumor biology: herceptin acts as an anti-angiogenic cocktail. Nature 416:279.
32. Clynes, R. A., T. L. Towers, L. G. Presta, and J. V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6:443.
33. Trapani, J. A., and M. J. Smyth. 2002. Functional significance of the perforin/granzyme cell death pathway. Nat. Rev. Immunol. 2:735.
34. Sallusto, F., C. R. Mackay, and A. Lanzavecchia. 2000. The role of chemokine receptors in primary, effector, and memory immune responses. Annu. Rev. Immunol. 18:593.
35. Rosenberg, S. A., B. S. Packard, P. M. Aebersold, D. Solomon, S. L. Topalian, S. T. Toy, P. Simon, M. T. Lotze, J. C. Yang, C. A. Seipp, et al. 1988. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report. N. Engl. J. Med. 319:1676.
36. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850.
37. Weijtens, M. E., E. H. Hart, and R. L. Bolhuis. 2000. Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production. Gene Ther. 7:35.
38. Mantovani, L. T., S. Miotti, S. Menard, S. Canevari, F. Raspagliesi, C. Bottini, F. Bottero, and M. I. Colnaghi. 1994. Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19. Eur. J. Cancer 30A:363.
39. Bonini, C., G. Ferrari, S. Verzeletti, P. Servida, E. Zappone, L. Ruggieri, M. Ponzoni, S. Rossini, F. Mavilio, C. Traversari, and C. Bordignon. 1997. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276:1719.
40. Ciceri, F., C. Bonini, S. Marktel, E. Zappone, P. Servida, S. Rossini, M. Bernardi, A. Pescarollo, M. Bregni, P. Corradini, et al. 1999. Long-term follow-up in 30 patients receiving HSV-TK-transduced donor lymphocytes after allo-BMT. Blood 94:2963.
41. Schwartzentruber, D. J. 2001. Guidelines for the safe administration of high-dose interleukin-2. J. Immunother. 24:287.